The omega-3 fatty acids EPA and DHA decrease plasma F2- isoprostanes: Results from two placebo-controlled interventions

Free Radical Research

Volumn 44, Issue 9, 2010, Pages 983-990

  Mas, Emilie ^a   Woodman, Richard J ^a   Burke, Valerie ^a   Puddey, Ian B ^a   Beilin, Lawrence J ^a   Durand, Thierry ^b   Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

fish oil; inflammation; Isoprostanes

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; ISOPROSTANE DERIVATIVE; OMEGA 3 FATTY ACID; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; F2-ISOPROSTANES; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; YOUNG ADULT;

EID: 77956378464     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2010.492830     Document Type: Article

References (54)

1. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008;10:1405-1434.
2. Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts LJ, 2nd, Burk RF. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 1992;90:2502-2507.
3. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ, 2nd. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992;89:10721-10725.
4. Basu S, Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 2005;7:221-235.
5. Kono N, Inoue T, Yoshida Y, Sato H, Matsusue T, Itabe H, Niki E, Aoki J, Arai H. Protection against oxidative stress-induced hepatic injury by intracellular type II platelet-activating factor acetylhydrolase by metabolism of oxidized phospholi-pids in vivo. J Biol Chem 2008;283:1628-1636.
6. Stafforini DM, Sheller JR, Blackwell TS, Sapirstein A, Yull FE, McIntyre TM, Bonventre JV, Prescott SM, Roberts LJ, 2nd. Release of free F2-isoprostanes from esterifi ed phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 2006;281:4616-4623.
7. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A, Wachsman JT, Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ, 2nd, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710.
8. Nourooz-Zadeh J, Liu EH, Anggard E, Halliwell B. F4-iso-prostanes: a novel class of prostanoids formed during peroxi-dation of docosahexaenoic acid (DHA). Biochem Biophys Res Commun 1998;242:338-344.
9. Musiek ES, Cha JK, Yin H, Zackert WE, Terry ES, Porter NA, Montine TJ, Morrow JD. Quantifi cation of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosa-hexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. J Chromatogr B Analyt Technol Biomed Life Sci 2004;799:95-102.
10. Roberts LJ, 2nd, Fessel JP, Davies SS. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol 2005;15:143-148.
11. Yin H, Musiek ES, Gao L, Porter NA, Morrow JD. Regi-ochemistry of neuroprostanes generated from the peroxida-tion of docosahexaenoic acid in vitro and in vivo. J Biol Chem 2005;280:26600-26611.
12. Nourooz-Zadeh J, Halliwell B, Anggard EE. Evidence for the formation of F3-isoprostanes during peroxidation of eicosap-entaenoic acid. Biochem Biophys Res Commun 1997;236: 467-472. (Pubitemid 27373321)
13. Lawson JA, Kim S, Powell WS, FitzGerald GA, Rokach J. Oxidized derivatives of omega-3 fatty acids: identifi cation of IPF3 alpha-VI in human urine. J Lipid Res 2006;47:2515-2524.
14. Song WL, Paschos G, Fries S, Reilly MP, Yu Y, Rokach J, Chang CT, Patel P, Lawson JA, Fitzgerald GA. Novel EPA-derived F3-isoprostanes as biomarkers of lipid peroxidation. J Biol Chem 2009;35:23636-23643.
15. Gao L, Yin H, Milne GL, Porter NA, Morrow JD. Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem 2006;281: 14092-14099.
16. Yin H, Liu W, Goleniewska K, Porter NA, Morrow JD, Peebles RS, Jr. Dietary supplementation of omega-3 fatty acid-containing fish oil suppresses F(2)-isoprostanes but enhances inflammatory cytokine response in a mouse model of ovalbumin-induced allergic lung infl ammation. Free Radic Biol Med 2009;47:622-628.
17. Mori TA. Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation. Redox Rep 2004;9:193-197.
18. Streppel MT, Ocke MC, Boshuizen HC, Kok FJ, Kromhout D. Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zut-phen study. Eur Heart J 2008;29:2024-2030.
19. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fi bre intakes on death and myocardial reinfarc-tion: diet and reinfarction trial (DART). Lancet 1989;2: 757-761.
20. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009;2:535-539.
21. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372: 1223-1230.
22. Mori TA BV, Beilin LJ. Dietary fats and blood pressure. In: Lip GYH, Hall JE., editors. Comprehensive hypertension section I: epidemiology. Philadelphia, USA: Elsevier; 2007. p. 77-88.
23. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585-594.
24. Mori TA, Dunstan DW, Burke V, Croft KD, Rivera JH, Beilin LJ, Puddey IB. Effect of dietary fish and exercise training on urinary F2-isoprostane excretion in non-insulin-dependent diabetic patients. Metabolism 1999;48:1402-1408.
25. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexae-noic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003;35:772-781.
26. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipi-demic men. Am J Clin Nutr 2000;71:1085-1094.
27. Barden AE, Mori TA, Dunstan JA, Taylor AL, Thornton CA, Croft KD, Beilin LJ, Prescott SL. Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Radic Res 2004;38:233-239.
28. Durand T, Guy A, Vidal JP, Viala J, Rossi JC. Total synthesis of 4(RS)-F4t-isoprostane methyl ester. Tetrahedron Lett 2000;41:3859-3862.
29. Mori TA, Croft KD, Puddey IB, Beilin LJ. An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Anal Biochem 1999;268:117-125.
30. Quaggiotto P, Leitch JW, Falconer J, Murdoch RN, Garg ML. Plasma F2[alpha]-isoprostane levels are lowered in pigs fed an (n-3) polyunsaturated fatty acid supplemented diet following occlusion of the left anterior descending coronary artery. Nutr Res 2000;20:675-684.
31. Higdon JV, Liu J, Du SH, Morrow JD, Ames BN, Wander RC. Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes. Am J Clin Nutr 2000;72:714-722.
32. Nalsen C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, Rivellese A, Storlien L, Erkkila A, Yla-Herttuala S, Tapsell L, Basu S. Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans. J Nutr 2006;136:1222-1228.
33. Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyun-saturated fatty acids as antioxidants. Pharmacol Res 2008;57: 451-455.
34. Maziere C, Dantin F, Conte MA, Degonville J, Ali D, Dubois F, Maziere JC. Polyunsaturated fatty acid enrichment enhances endothelial cell-induced low-density-lipoprotein peroxidation. Biochem J 1998;336:57-62.
35. Visioli F, Colombo C, Galli C. Oxidation of individual fatty acids yields different profi les of oxidation markers. Biochem Biophys Res Commun 1998;245:487-489.
36. Yazu K, Yamamoto Y, Niki E, Miki K, Ukegawa K. Mechanism of lower oxidizability of eicosapentaenoate than linoleate in aqueous micelles. II. Effect of antioxidants. Lipids 1998;33: 597-600.
37. Davis TA, Gao L, Yin H, Morrow JD, Porter NA. In vivo and in vitro lipid peroxidation of arachidonate esters: the effect of fish oil omega-3 lipids on product distribution. J Am Chem Soc 2006;128:14897-14904.
38. Xu L, Davis TA, Porter NA. Rate constants for peroxidation of polyunsaturated fatty acids and sterols in solution and in liposomes. J Am Chem Soc 2009;131:13037-13044.
39. Mori TA, Beilin LJ. Omega-3 fatty acids and infl ammation. Curr Atheroscler Rep 2004;6:461-467.
40. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 2002;61:345-358.
41. Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009;91: 791-795.
42. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003;38:343-352.
43. Yaqoob P, Calder P. Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages. Cell Immunol 1995;163:120-128
44. Calder PC. n-3 polyunsaturated fatty acids and cytokine production in health and disease. Ann Nutr Metab 1997;41:203-234.
45. Khalfoun B, Gruel Y, Bardos P, Lebranchu Y. Docosahexae-noic and eicosapentaenoic acids inhibit in vitro human lymphocyte proliferation induced by allogenic cells. Transplant Proc 1997;29:2397. (Pubitemid 27373756)
46. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of inter-leukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-271.
47. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996;63: 116-122.
48. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA, Gorbach SL. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1991;121:547-555.
49. Kelley DS, Taylor PC, Nelson GJ, Schmidt PC, Ferretti A, Erickson KL, Yu R, Chandra RK, Mackey BE. Docosahexae-noic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids 1999;34:317-324.
50. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008;3: 279-312.
51. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278: 14677-14687.
52. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infi ltration and pro-inflammatory gene expression. J Biol Chem 2003;278: 43807-43817.
53. Serhan CN, Chiang N, Van Dyke TE. Resolving inflamma-tion: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-361.
54. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-1037.